Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanosonics Limited ( (AU:NAN) ) has issued an announcement.
Nanosonics reported that its trophon installed base has reached 38,080 cumulative units, underscoring its strong position in ultrasound probe reprocessing and its role in protecting millions of patients each year. The company is now progressing the phased commercialisation of its CORIS platform, signalling an expansion into endoscope reprocessing that could significantly broaden its addressable market and reinforce its standing in the global infection prevention landscape.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited operates in the medical technology sector, specialising in infection prevention through transformative device reprocessing technologies. Its flagship trophon system has established market leadership in ultrasound probe reprocessing, while the company is also advancing CORIS, a platform aimed at improving endoscope reprocessing and patient safety worldwide.
YTD Price Performance: -5.04%
Average Trading Volume: 411,916
Technical Sentiment Signal: Sell
Current Market Cap: A$1.09B
For detailed information about NAN stock, go to TipRanks’ Stock Analysis page.